RT Journal Article
SR Electronic
T1 Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP p4407
VO 38
IS Suppl 55
A1 Maryna Dziusmikeyeva
A1 Aksana Zalutskaya
A1 Aliaksandr Skrahin
A1 Aleh Prasmyzki
A1 Varvara Solodovnikova
A1 Alena Skrahina
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/p4407.abstract
AB Setting: The known determinants of drug-resistance development are non-compliance with prescribed treatment. Clinical management of multidrug-resistant tuberculosis (MDR-TB) requires lengthy multidrug regimens that often cause adverse events. Interruptions in treatment may result from the adverse events.Design: We retrospectively reviewed medical records of 220 patients with MDR-TB who received individualized treatment in accordance with the recommendations of the WHO. A multiple logistic regression model was performed to determine whether the occurrence of adverse reactions was associated with poor treatment outcome.Results: One or more adverse events were observed in all patients in the study. With an average of one patient receiving treatment, noted 10.4 episodes of adverse events. The most commonly reported events were nausea and vomiting (61%), dizziness (56%), abdominal pain (39%), arthralgia (31%), ototoxicity (19%) and dermatological effects (19%), psychiatric disorders (8%), hepatitis (4%) and renal failure (3%). These events led the clinicians to change in drug dose or withdraw one or more drugs from the treatment regimen temporarily or permanently.Conclusion: Antituberculous drugs adverse events and connected with them treatment interruptions are observed more often in treatment of MDR-TB. MDR-TB patients who are female, older or have severe TB disease should be closely monitored for treatment-related adverse events. Obtained data allow to predict possible adverse events of MDR-TB chemotherapy, to provide the availability of medications necessary for adverse events reduction, including emergency cases.